rate of combination sorafenib and temsirolimus in I-131 refractory thyroid cancer Secondary Outcome Measures: Evaluate if the presence of BRAF mutations, with or without concomitant mutations in the PI3K AKT, mTOR pathway, predicts
Search Results
Oncology Research Program
NCCN News
develop studies to scientifically evaluate and define GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor. Previous research has indicated that BRAF mutations are strong targets for therapies in the treatment of advanced melanoma
NCCN Guidelines Insights: Melanoma, Version 3.2016
Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Brian Gastman, Rene Gonzalez, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh
with single-agent ipilimumab. Both these trials also showed substantially increased toxicity with immune checkpoint combination therapy versus monotherapy. Anti–PD-1 Therapy in Patient Subpopulations: BRAF Mutation Status: Subgroup analyses in the
Systemic Therapy for Metastatic Melanoma in 2012: Dawn of a New Era
Shailender Bhatia and John A. Thompson
V600R). 25 The absolute and relative frequencies of the different mutations of BRAF are age-dependent, with an inverse relationship between age and BRAF mutation rate and a higher proportion of V600K mutations in older patients. 26 Earlier
How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?
Sanam Loghavi, Mark J. Routbort, Keyur P. Patel, Rajyalakshmi Luthra, Wei-Lien Wang, Russell R. Broaddus, Michael A. Davies, and Alexander J. Lazar
cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011 ; 29 : 2011 – 2019 . 26. Hutchins G Southward K Handley K . Value of mismatch repair, KRAS, and BRAF mutations in predicting
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann, and Lisa A. Gurski
with BRAF mutation–positive DTCs that are locally recurrent, advanced, and/or metastatic, are not surgically resectable, are not amenable to RAI, and are progressing and/or symptomatic (see PAP-9, page 1433). The decision was made to not specify BRAF
Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas
Anastasia Drobysheva, Laura J. Klesse, Daniel C. Bowers, Veena Rajaram, Dinesh Rakheja, Charles F. Timmons, Jason Wang, Korgun Koral, Lynn Gargan, Erica Ramos, and Jason Y. Park
); only 1 of the 17 patients had a BRAF mutation, and no patients had mutations in HRAS, KRAS, NRAS , or FGFR1 on targeted analysis. 18 Frequent MAPK pathway activation through fusion and nonfusion mutations has been recognized as a potential target
Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer
Axel Grothey and Alan P. Venook
from the IDEA study for adjuvant treatment of colon cancer. advanced disease. Tumors should be evaluated for KRAS, NRAS , and BRAF status, either individually or as part of a next-generation sequencing panel. KRAS and BRAF mutations are
A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy
Lindsey M. Charo, Adam M. Burgoyne, Paul T. Fanta, Hitendra Patel, Juliann Chmielecki, Jason K. Sicklick, and Michael T. McHale
neurodegenerative dementia 22 but are not well-associated with human cancer. According to several studies, approximately 1% of GISTs possess BRAF mutations, which are most often canonical V600E seen in other tumor types, including melanoma and colon cancer. 3
Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer
Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming
anti-EGFR therapy in patients with tumors harboring KRAS, NRAS , and BRAF mutations, which are commonly enriched within the right-sided primary population. 25 – 27 When stratified for sidedness, prospective targeted sequencing panels have revealed
